Oncogenic Function of a P53-Induced Phosphatase

描述(申请人提供)：在大多数人类肿瘤中，肿瘤抑制基因P53在结构或功能上是失活的。在那些保持P53结构完整的肿瘤中，P53信号通常通过改变P53调节因子的表达而被激活，如MDM2或ARF。我们一直在研究编码丝氨酸/苏氨酸磷酸酶Wip1(也称为PPM1D)的p53转录靶点。与MDM2和ARF一样，Wip1似乎也调节P53的功能。我们发现Wip1通过多个机制抑制P53的功能，包括(1)去磷酸化和抑制P53激酶，(2)去磷酸化P53本身，和(3)去磷酸化和稳定MDM2，从而导致P53的降解。除了对P53的抑制作用外，我们还发现Wip1去磷酸化了一些蛋白质，这些蛋白质在细胞DNA损伤反应中被ATM和ATR激酶磷酸化。我们假设，Wip1作为DNA损伤反应的动态平衡调节器，促进损伤细胞在损伤修复后返回到压力前状态。Wip1对p53的负性作用使Wip1成为一个明显的癌基因候选基因。事实上，乳腺癌和其他几种人类癌症都表现出Wip1基因的放大和过度表达。此外，Wip1在啮齿动物成纤维细胞转化试验中扮演癌基因的角色，我们已经证明缺乏Wip1的小鼠对肿瘤具有抵抗力。为了更好地了解Wip1在肿瘤发生和DNA损伤反应调控中的作用，我们提出了三个特定的目标。目的1通过对Wip1催化位点的诱变和对Wip1/靶蛋白相互作用结构域的研究，重点研究Wip1的结构/功能关系。目的2对在ATM/ATR介导的DNA损伤反应中起重要作用的新的Wip1靶点进行鉴定和功能鉴定。最后，Aim 3将使用基因工程小鼠模型在活体环境中检查ATM/Wip1和P53/Wip1的相互作用以及Wip1介导的基因组完整性。公共卫生相关性：我们建议研究p53调控的癌基因Wip1的功能，该基因在细胞周期控制和DNA损伤反应中发挥重要作用。Wip1是一种致癌的磷酸酶，部分原因是它抑制了P53的功能。具体地说，我们计划研究Wip1的结构，确定Wip1的新靶点，它如何与这些靶点相互作用，以及这种相互作用的功能后果。最后，我们想了解Wip1是如何影响完好的哺乳动物--小鼠的生理过程的。

DESCRIPTION (provided by applicant): The tumor suppressor p53 is structurally or functionally inactivated in most human tumors. In those tumors that retain structurally intact p53, p53 signaling is often activated through altered expression of p53 regulators, such as Mdm2 or ARF. We have been investigating a p53 transcription target that encodes the serine/threonine phosphatase Wip1 (also known as PPM1D). Like Mdm2 and ARF, Wip1 appears to regulate p53 function. We have shown that Wip1 inhibits p53 function through multiple mechanisms, including (1) dephosphorylation and inhibition of p53 kinases, (2) dephosphorylation of p53 itself, and (3) dephosphorylation and stabilization of Mdm2, which leads to p53 degradation. In addition to its inhibitory effects on p53, we have also shown that Wip1 dephosphorylates a number of proteins that are phosphorylated by the ATM and ATR kinases in the cellular DNA damage response. We hypothesize that Wip1 acts as a homeostatic regulator of the DNA damage response by facilitating the return of the damaged cell back to a pre-stress state once damage is repaired. The negative effects of Wip1 on p53 make Wip1 an obvious oncogene candidate. In fact, breast cancers and several other human cancer types display amplification and overexpression of the Wip1 gene. Moreover, Wip1 acts as an oncogene in rodent fibroblast transformation assays and we have shown that mice lacking Wip1 are resistant to tumors. To better understand Wip1 function in oncogenesis and regulation of the DNA damage response, we propose three specific aims. Aim 1 will focus on Wip1 structure/function relationships through mutagenic ascertainment of the Wip1 catalytic site and by examination of Wip1/target protein interaction domains. Aim 2 entails the identification and functional characterization of novel Wip1 targets important in the ATM/ATR-mediated DNA damage response. Finally, Aim 3 will use genetically engineered mouse models to examine ATM/Wip1 and p53/Wip1 interactions as well as Wip1-mediated genomic integrity in an in vivo context. PUBLIC HEALTH RELEVANCE: We propose to investigate the functions of a p53 regulated oncogene, Wip1, that plays an important role in cell cycle control and the DNA damage response. Wip1 is a phosphatase that is oncogenic in part because it inhibits p53 function. Specifically, we plan to study the structure of Wip1, identify new targets of Wip1, how it interacts with those targets, and the functional consequences of such interactions. Finally, we would like to understand how Wip1 effects physiological processes in an intact mammal, the mouse.